DOP2017000196A - Derivados de tetrahidropiranil benzamida - Google Patents

Derivados de tetrahidropiranil benzamida

Info

Publication number
DOP2017000196A
DOP2017000196A DO2017000196A DO2017000196A DOP2017000196A DO P2017000196 A DOP2017000196 A DO P2017000196A DO 2017000196 A DO2017000196 A DO 2017000196A DO 2017000196 A DO2017000196 A DO 2017000196A DO P2017000196 A DOP2017000196 A DO P2017000196A
Authority
DO
Dominican Republic
Prior art keywords
tetrahidropiranil
benzamida
derivatives
compounds
prepare
Prior art date
Application number
DO2017000196A
Other languages
English (en)
Inventor
Ma Tianwei
Long Hu Zhi
Zhu LIU Lian
Zhang Haizhen
Zhou Jingye
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2017000196A publication Critical patent/DOP2017000196A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula siguiente: en donde R, R1-R3 son como se describen en la presente; métodos para tratar pacientes por diabetes usando los compuestos, y procesos para preparar los compuestos.
DO2017000196A 2015-03-03 2017-08-21 Derivados de tetrahidropiranil benzamida DOP2017000196A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/073563 WO2016138631A1 (en) 2015-03-03 2015-03-03 Imidazo benzamide compounds

Publications (1)

Publication Number Publication Date
DOP2017000196A true DOP2017000196A (es) 2017-09-15

Family

ID=56849060

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000196A DOP2017000196A (es) 2015-03-03 2017-08-21 Derivados de tetrahidropiranil benzamida

Country Status (24)

Country Link
US (1) US10196385B2 (es)
EP (1) EP3265460A4 (es)
JP (1) JP2018507232A (es)
KR (1) KR20170106483A (es)
CN (1) CN107406436B (es)
AU (1) AU2016228055B2 (es)
BR (1) BR112017015448A2 (es)
CA (1) CA2975413A1 (es)
CL (1) CL2017002148A1 (es)
CO (1) CO2017008721A2 (es)
CR (1) CR20170354A (es)
DO (1) DOP2017000196A (es)
EA (1) EA201791745A1 (es)
EC (1) ECSP17058071A (es)
IL (1) IL253405A0 (es)
MA (1) MA41641A (es)
MX (1) MX2017011087A (es)
PE (1) PE20171650A1 (es)
PH (1) PH12017501560A1 (es)
SG (1) SG11201706718RA (es)
SV (1) SV2017005520A (es)
TN (1) TN2017000372A1 (es)
WO (2) WO2016138631A1 (es)
ZA (1) ZA201704948B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014337A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2010101247A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Npy y5受容体拮抗作用を有するシクロヘキサン誘導体
CA2785790A1 (en) * 2010-01-15 2011-07-21 Merck Sharp & Dohme Corp. Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound

Also Published As

Publication number Publication date
CA2975413A1 (en) 2016-09-09
PE20171650A1 (es) 2017-11-13
BR112017015448A2 (pt) 2018-01-30
US10196385B2 (en) 2019-02-05
SG11201706718RA (en) 2017-09-28
JP2018507232A (ja) 2018-03-15
ECSP17058071A (es) 2017-10-31
EA201791745A1 (ru) 2018-01-31
TN2017000372A1 (en) 2019-01-16
IL253405A0 (en) 2017-09-28
MX2017011087A (es) 2017-11-10
AU2016228055B2 (en) 2018-06-07
CO2017008721A2 (es) 2018-01-05
KR20170106483A (ko) 2017-09-20
MA41641A (fr) 2018-01-09
WO2016138821A1 (en) 2016-09-09
CN107406436B (zh) 2021-02-26
US20180194755A1 (en) 2018-07-12
CN107406436A (zh) 2017-11-28
PH12017501560A1 (en) 2018-02-05
EP3265460A4 (en) 2018-08-08
CR20170354A (es) 2017-09-05
AU2016228055A1 (en) 2017-08-17
EP3265460A1 (en) 2018-01-10
WO2016138631A1 (en) 2016-09-09
ZA201704948B (en) 2019-02-27
SV2017005520A (es) 2018-08-27
CL2017002148A1 (es) 2018-04-13

Similar Documents

Publication Publication Date Title
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
BR112016023558A2 (pt) compostos úteis como imunomoduladores
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
EA201692219A1 (ru) Способы получения противовирусных соединений
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CY1124164T1 (el) Καινοτομος παρασκευη και κρυσταλλωση της ιοσιμενολης
PE20180219A1 (es) Procesos para preparar fluorocetolidos
BR112017016333A2 (pt) compostos anticâncer
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
BR112017012007A2 (pt) compostos orgânicos
CL2017002304A1 (es) Métodos para tratar enfermedades